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244Objective: The preventative effect of statins on postoperative atrial fibrillation has been hypothesized. However,
all studies to date have examined patients who did not receive statins before their further allocation to treatment or
no treatment. Because guidelines recommend the routine use of statins in patients with coronary artery disease, we
set out to examine the effect of intensive statin pretreatment versus continuation of usual statin dose on atrial fi-
brillation after cardiac surgery.
Methods: Patients receiving routine statin treatment and undergoing coronary artery bypass surgery or aortic
valve replacement with no history of atrial fibrillation or antiarrhythmic medication were randomized to receive
atorvastatin 80mg or atorvastatin 10 mg for 7 days before surgery in a single-blind fashion. The primary end point
was the development of postoperative atrial fibrillation during hospital stay.
Results:A total of 104 consecutive patients were included. Postoperative atrial fibrillation occurred in 33 patients
(32.4%). No significant differences were found in demographics, medical history, or intraoperative variables be-
tween treatment groups, with the exception of higher rate of b-blocker use in the atorvastatin 10 mg group (75%
vs 53%, P¼ .002) and previous myocardial infarction (62% vs 42%, P¼ .049). The incidence of postoperative
atrial fibrillation was lower in the atorvastatin 80 mg group when compared with the atorvastatin 10 mg group, but
this difference did not reach statistical significance (29% vs 36%, P ¼ .43).
Conclusions: High-dose atorvastatin for 7 days before cardiac surgery conferred a nonsignificant reduction in
postoperative atrial fibrillation when compared with a low-dose regimen. A larger study would be necessary to
confirm the beneficial effect of high-dose statins in this setting. (J Thorac Cardiovasc Surg 2011;141:244-8)Atrial fibrillation (AF) after cardiac surgery is associated
with prolonged hospital stay, increased overall morbidity,
and long-term mortality.1 The identification of agents
with a potential modulatory effect on the substrate respon-
sible for AF has led to clinical studies assessing the appli-
cability of these ‘‘upstream therapies’’ in the prevention
of postoperative AF.2 The antiarrhythmic role of statins
has previously been examined against the background of
different cardiovascular conditions with variable results.
The preventative effect of statins on the development of
AF after cardiac surgery has also been suggested, based
on various observational studies, randomized controlled tri-
als, and meta-analyses.3 Our group previously validated
that statins could be protective against postoperative AF,
but, more important, that this effect is dose-dependent.4
In all prospective controlled studies to date, the potential
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The Journal of Thoracic and Cardiovascular Surgor nontreatment control groups.5,6 Although this observation
is of great research interest, its clinical applicability is
limited because the majority of patients undergoing
cardiac surgery receive statins as part of their disease
management. Therefore, and in view of the possible dose-
related effect of statins, we set out to examine the impact
of 7-day preoperative treatment with high (80 mg) versus
usual (10 mg) doses of atorvastatin in the development of
postoperative AF in patients who had previously received
routine statin therapy. Thus, the prospective role of intensive
statin treatment in the prevention of AF after cardiac surgery
was studied, with the potential to influence routine clinical
practice in the perioperative management of these patients.MATERIALS AND METHODS
This study was a randomized, controlled, single-blinded trial examining
the effect of 7-day pretreatment with atorvastatin 80 mg versus atorvastatin
10 mg on the incidence of AF after cardiac surgery in patients already re-
ceiving routine statin treatment. The primary end point was the development
of postoperative AF during hospital stay. Ethical approval was obtained,
and all participants gave informed written consent. Approval from Medi-
cines and Healthcare products Regulatory Agency was also obtained (Eu-
draCT 2006-005272-40). This study was included in the International
Standard Randomised Controlled Trial Number Register (41309956). The
design, analysis, and reporting of data derived from this randomized con-
trolled trial were carried out according to CONSORT recommendations.7
A total of 123 consecutive patients undergoing elective first-time coro-
nary artery bypass grafting (CABG) or aortic valve replacement by a single
surgeon were randomized in a single-blind fashion between April 2007 andery c January 2011
TABLE 1. Patient characteristics and operative variables between the
low- and high-dose statin groups
Variable
Atorvastatin
10 mg (n ¼ 53)
Atorvastatin
80 mg (n ¼ 49)
P
value
Age (y) 66  9.2 66  8.5 .95
Male 47 (89) 42 (86) .65
Medical history
Hypertension 36 (68) 33 (67) .95
Diabetes 12 (23) 8 (16) .42
Previous TIA 1 (2) 4 (8) .19
COPD 4 (8) 4 (8) 1.00
Medications
b-blockers 40 (75) 26 (53) .018
ACEIs 38 (72) 29 (59) .18
Cardiac history
CCS class III–IV 5 (9) 8 (16) .55
NYHA class III–IV 8 (15) 79 (16) .47
Previous MI 33 (62) 21 (43) .05
LVEF<50% 13 (25) 10 (20) .62
Operative characteristics
CABG 47 (89) 46 (94) .49
Off-pump 13 (25) 13 (27) .82
CABGþAVR 3 (6) 1 (2) .62
AVR 9 (17) 4 (8) .18
CPB time (min) 65  44 65  51 .84
Crossclamp time (min) 41  28 41  31 .81
euroSCORE 2.87  1.7 2.63  1.7 .56
Postoperative AF 19 (35.9) 14 (28.6) .43
TIA, Transient ischemic attack; COPD, chronic obstructive pulmonary disease; ACEI,
angiotensin-converting enzyme inhibitor; CCS, Canadian Cardiovascular Society;
NYHA,NewYork Heart Association;MI,myocardial infarction; LVEF, left ventricular
ejection fraction; CABG, coronary artery bypass graft; AVR, aortic valve replacement;
CPB, cardiopulmonary bypass; euroSCORE, European System for Cardiac Operative
Risk Evaluation; AF, atrial fibrillation. Categoric data are numbers (%); continuous
data as means  standard deviation.
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
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(atorvastatin 10 or 20 mg; simvastatin 10, 20, or 40 mg) were randomized
to atorvastatin 10 or 80 mg. Patients receiving intensive statin therapy
(atorvastatin 40 or 80 mg; simvastatin 80 mg) before surgery were excluded.
Additional exclusion criteria were as follows: history of atrial arrhythmias;
treatment with antiarrhythmic agents (except b-blockers); valve surgery
other than aortic; hepatobiliary disease; unexplained persistent elevations
in serum transaminases; increased consumption of alcohol; consistent drink-
ing more than 4 U/d; serum creatinine greater than 180 mmol/L; known in-
tolerance to statins or myopathy; cyclosporin, fibric acid derivatives,
erythromycin, niacin, or azole antifungal use; and pregnant or breastfeeding
women.
Patients were evaluated in a preassessment clinic at St George’s Hos-
pital, London, at least 2 weeks before surgery and were randomized at the
time. Statins were delivered to the patient in an appropriately numbered
container by a member of administrative staff, independent of the trial.
Allocated atorvastatin treatment was then commenced 7 days before sur-
gery, and the usual statin therapy was discontinued at that time. Study
medication was continued for 14 days after surgery or until discharge
(whichever first). Daily administration of statins during hospital stay
was carried out by the on-duty nursing staff. Patients were reassessed
on completion of the trial medication just before hospital discharge or
at 2 weeks after surgery and were prescribed their preoperative statin
type and dose. At this point, the same (independent of the trial) member
of administrative staff received the empty skillet and blisters from the pa-
tient and checked compliance. Thus, ensuring that the investigator was not
inadvertently unblinded during the course of the study (skillets were never
opened and tablets were administered in the presence of an investigator).
In addition, a tamper-evident seal on the external skillet was applied to
secure blinding.
Randomization was performed by an international clinical trials agency
(Richmond Pharmacology, London, UK) that provided the statistician,
randomization algorithm (computerized random number generation), and
external quality assurance.
Standardized surgical and anesthetic protocols were used as published
previously.8 Routine postoperative heart rhythm assessment was achieved
with continuous telemonitoring for the first 72 hours after surgery and
with 4-hourly clinical examinations thereafter. Twelve-lead electrocardio-
grams were also obtained and assessed daily.P
MStatistical Analysis and Sample Size Calculation
To estimate the appropriate sample size for difference in proportions (de-
velopment of postoperative AF) in equally sized treatment groups, data were
obtained from an observational study previously carried out by our group.4
Having examined the variable effect of different statin doses, we hypothe-
sized that the high-dose treatment group would exhibit an incidence of
AF in the same region, at least, as the one previously observed with simvas-
tatin 40 mg (15.6%). Conversely, we anticipated that the incidence of AF in
the low-dose group (atorvastatin 10 mg) would be similar to the one
achieved by the same type and dose in the observational study (41.9%).
On the basis of an estimated proportion for postoperative AF of 16%
(p1) in the atorvastatin 80 mg group and a proportion of 42% (p2) in the
atorvastatin 10 mg group, sample size was calculated using the following
established formula.9 Note that n equals the number of subjects required
in each group and that the coefficient Cp, power equals 10.5 to achieve
a P value of .05 and an alpha power of 90%.The Journal of Thoracic and Can ¼ ½p1ð1p1Þ þ p2ð1p2Þðp1 p2Þ 3 Cp;power
For the values p1 ¼ 0.16, p2 ¼ 0.42 and Cp,power ¼ 10.5 we calculate
n ¼ 58.7
A total population of 123 patients was decided on the basis of a 1:1 ran-
domization, allowing for the subsequent exclusion of 5 patients in case of
refusal to participate after allocation, cancellations, and so forth.
Univariate analysis was performed, with postoperative AF being the de-
pendent variable according to high or low atorvastatin dose. Dichotomous
data were evaluated using Pearson’s chi-square test or Fisher’s exact test,
whereas the t test and Mann–Whitney U test were used for continuous vari-
ables with normal or nonparametric distribution, respectively. Variables
with statistical significance less than 0.2 (with the inclusion of atorvastatin
80 mg use) were entered into a multivariate regression model to identify
independent predictors of postoperative AF. Statistical analysis was
performed with SPSS 17.0 software (SPSS Inc, Chicago, Ill).
RESULTS
A total of 102 patients were analyzed, 53 of whom re-
ceived atorvastatin 10 mg and 49 of whom received atorvas-
tatin 80 mg. Patient characteristics and operative variables
between the 2 treatment groups are shown in Table 1.
Twenty-one patients were excluded from the analysis.rdiovascular Surgery c Volume 141, Number 1 245
FIGURE 1. Flow diagram of randomized controlled trial. AF, Atrial fibrillation.
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MIn the majority of cases (n ¼ 12), patients did not complete
the full 7 days of atorvastatin treatment before surgery,
mainly because of unforeseen changes in the operating
schedule. For the remaining 9 patients, 4 decided not to
take the trial medication and continue with their standard sta-
tin, 1 lost the pack containing the atorvastatin, 1 underwent
emergency surgery, 1 underwent surgery in a different hos-
pital, and 2 decided not to undergo surgery. A flow diagram
of the randomized controlled trial is shown in Figure 1.
No significant differences were found in demographics,
medical history, or intraoperative variables between treat-
ment groups, with the exception of higher rate of b-blocker
use in the atorvastatin 10 mg group (75% vs 53%, P¼ .002)
and previous myocardial infarction (62% vs 42%,
P ¼ .049). The incidence of postoperative AF was lower
in the atorvastatin 80 mg group when compared with
atorvastatin 10 mg, but this difference was not statistically
significant (29% vs 36%, P ¼ .43) (Figure 2).FIGURE 2. Incidence of postoperative AF according to atorvastatin dose.
AF, Atrial fibrillation.
246 The Journal of Thoracic and Cardiovascular SurgPatient characteristics with the inclusion of atorvastatin 80
mg as an independent variable were entered into a multivar-
iate regression model to identify independent predictors of
AF development. Use of high-dose atorvastatin was rejected
at step 7 (of 13 steps) of the logistic regression. The remain-
ing independent variables associated with postoperative AF
are shown in Table 2.
The following postoperative complications occurred
while patients were still receiving atorvastatin treatment
and were promptly reported to the appropriate authorities:
One patient died of myocardial infarction 3 days after
CABG (received atorvastatin 10 mg, and AF developed on
the first postoperative day), and 1 patient had a stroke during
the hospital stay (received atorvastatin 80 mg).DISCUSSION
Evidence suggests a beneficial effect of statins on the
prevention of postoperative AF based on observational
studies,4,10-14 2 randomized controlled trials,5,6 and 2 meta-
analyses.15,16 Because of the consistency of the results
from these studies, statin use is a recommended modality
for the prevention of AF after cardiac surgery.2 More re-
cently, however, a retrospective propensity-adjusted analy-
sis by Virani and colleagues17 showed no effect of statin
use on postoperative AF, whereas in a similar study by Mi-
celi and colleagues,18 statins were found to be positively as-
sociated with AF after CABG. The differential risk profile of
patients receiving statins during this 10-year period and the
known underreporting of arrhythmia outcomes in various
registries may have led to this controversial result.
A common denominator of all relevant studies to date is
that the possible effect of statins on postoperative AF was
examined against patients who did not receive any statinsery c January 2011
TABLE 2. Independent predictors of postoperative atrial fibrillation
Variable Coefficient Standard error Odds ratio 95% CI P value
CCS score 0.70 0.36 2.02 1.00–4.07 .049
Crossclamp time 0.05 0.02 1.05 1.00–1.09 .048
CABG 2.79 1.30 0.06 0.01–0.70 .032
Age 0.12 0.04 1.13 1.05–1.21 .002
Constant 11.13 3.30 — — <.001
CI, Confidence interval; CCS, Canadian Cardiovascular Society; CABG, coronary artery bypass grafting.
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Mpreoperatively. It is recommended that statins be used in all
patients with coronary artery disease undergoing surgery, ir-
respective of their lipid profile, unless contraindicated.19 As
a result, even in earlier retrospective studies the control no-
statin group comprised less than 20% of the overall cohort.
This is why the identification of the beneficial effect of sta-
tins on postoperative AF over placebo or no treatment has
limited applicability in day-to-day practice.
This study sought to investigate whether intensive ator-
vastatin pretreatment could confer significant reduction in
postoperative AF over continuation of usual atorvastatin
dose in patients who already received routine statin therapy.
In addition to validating the potential antiarrhythmic role of
statins in this setting, this study aimed at the development of
an efficacious modality to complement the otherwise limited
armamentarium against postoperative AF.
The identified 7.3% absolute risk reduction in the odds of
postoperative AF conferred by atorvastatin 80 mg is in line
with our original hypothesis. However, the lack of statistical
significance (P¼ .43) limits any definitive conclusions from
being drawn. Despite the use of unrestricted randomization
code and blinding of the investigator to participant treatment
allocation, a higher rate of b-blocker use was found in the
atorvastatin 10 mg group compared with the atorvastatin
80 group (75% vs 53%, P ¼ .018). Previous studies have
postulated the protective role of preoperative b-blockade
in postoperative AF,20 and this can partially explain the
smaller treatment effect of high-dose statins than that sug-
gested in our original hypothesis, which also determined
the sample size. For such an observed difference between
the 2 treatment groups, an adequately powered study would
have required more than 650 patients to achieve a P value of
.05 with an a power of 0.80. However, we can speculate that
if baseline b-blocker use was similar or standardized, then
patients receiving low-dose atorvastatin would exhibit
higher rates of postoperative AF (as shown in the observa-
tional study) and the treatment effect of intensive dose ator-
vastatin would possibly be more pronounced.Study Limitations
The decision for the number of subjects per treatment
group was made on appropriate power size calculation
with the allowance for approximately 5% of cancellation
and dropout rates. This rate was exceeded because 21 pa-The Journal of Thoracic and Catients were excluded after randomization, mainly because
of unanticipated changes in the operating schedule leading
to fewer days of treatment with the investigational medica-
tion. Inclusion of these patients, however, would not have
led to significantly different outcomes based on the treat-
ment effect observed by high-dose statins. Although all mea-
sures were taken for the investigators not to be inadvertently
unblinded, we accept that a double-blind study may have
eliminated any detection bias in the trial. In line with most
relevant studies to date, the method used for postoperative
AF monitoring may have led to underdetection of some
asymptomatic, self-terminating episodes of AF after the first
72 hours where continuous telemonitoring was used.
CONCLUSIONS
Although baseline lipid profile was routinely assessed be-
fore further allocation to investigational statin, data from
follow-up measurements were incomplete and therefore
not included in the analysis. The exact mechanism by which
statins may protect against AF was beyond the scope of this
study. However, we concur with previous investigators who
have suggested that the potential antiarrhythmic effect of
statins is independent of their lipid-lowering capacity.21 In
addition, we previously showed that equivalent statin doses
and types, based merely on their lipid-lowering efficacy, ex-
hibit a differential effect on AF prevention.22 Consequently,
we could not fully control for the impact of previously re-
ceived routine treatment with statins from that achieved by
the investigational dose atorvastatin.
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